donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IMVT Immunovant > Detailed Quotes

IMVT Immunovant

5.175
+0.015+0.29%
Trading Session 08/16 14:49 ET
High
5.450
Open
5.090
Turnover
1.51M
Low
5.020
Pre Close
5.160
Volume
287.46K
Market Cap
603.29M
P/E(TTM)
Loss
52wk High
9.535
Shares
116.58M
P/E(Static)
Loss
52wk Low
3.145
Float Cap
172.68M
Bid/Ask %
33.33%
Historical High
53.750
Shs Float
33.37M
Volume Ratio
0.92
Historical Low
3.145
Dividend TTM
--
Div Yield TTM
--
P/B
1.38
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.86%
Amplitude
8.33%
Avg Price
5.253
Lot Size
1
Float Cap
172.68M
Bid/Ask %
33.33%
Historical High
53.750
Shs Float
33.37M
Volume Ratio
0.92
Historical Low
3.145
Dividend TTM
--
P/B
1.38
Dividend LFY
--
Turnover Ratio
0.86%
Amplitude
8.33%
Avg Price
5.253
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
CEO: Salzmann M.B.A., M.D., Peter
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...